[1] YOKOTA T, OMACHI K, SUICO M A, et al.Bromide supplementation exacerbated the renal dysfunction injury and fibrosis in a mouse model of Alport syndrome[J]. PLoS One,2017,12(9):e183959.
[2] MALONE A F, FUNK S D, ALHAMAD T, et al.Functional assessment of a novel COL4A5 splice region variant and immunostaining of plucked hair follicles as an alternative method of diagnosis in X-Linked Alport syndrome[J]. Pediatr Nephrol,2017,32(6):997-1003.
[3] GROSS O, LICHT C, ANDERS H J, et al.Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy[J].Kidney Int,2012,81(5): 494-501.
[4] KRIZ W.The pathogenesis of classic focal segmental glomerulosclerosis-lessons from rat models[J].Nephrol Dial Transplant,2003,18(6):39-44.
[5] LIU Y.New insights into epithelial-mesenchymal transition in kidney fibrosis[J]. J Am Soc Nephrol,2010,21(2):212-222.
[6] YAMAMURA T, NOZU K, FU X J, et al.Natural history and genotype-phenotype correlation in female X-Linked Alport syndrome[J].Kidney Int Rep,2017,2(5):850-855.
[7] TEMME J,PETERS F,LANGE K,et al.Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations[J]. Kidney Int,2012,81(8):779-783.
[8] WEBB N J,LAM C,SHAHINFAR S,et al.Efficacy and safety of losartan in children with Alport syndrome-results from a subgroup analysis of a prospective,randomized,placebo-or amlodipine-controlled trial[J].Nephrol Dial Transplant,2011,26(8):2521-2526.
[9] KASHTAN C E,DING J,GREGORY M,et al.Clinical practice recommendations for the treatment of Alport syndrome:a statement of the Alport Syndrome Research Collaborative[J].Pediatr Nephrol,2013,28(1):5-11.
[10] DEY N,GHOSH-CHOUDHURY N,KASINATH B S,et al.TGFβ-stimulated micro-RNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion[J]. PLoS One,2012,7(8):e42316. |
